Search Results

Charles River Laboratories International, Inc. today announced a lentiviral vector contract development and manufacturing organization (CDMO) agreement.

FibroBiologics, Inc., (Nasdaq: FBLG) (“FibroBiologics”) and Charles River Laboratories (“Charles River”), a highly respected, global provider of drug discovery, development, and manufacturing solutions, today announced the signing of a letter of intent allowing for the transfer, testing and validation of FibroBiologics’ technology.

Charles River Laboratories International, Inc. today announced a plasmid DNA and retrovirus vector production program agreement.

New turnkey research facility will provide AAALAC-accredited flexible vivarium space for Massachusetts biopharmaceutical hub Charles River Laboratories International, Inc. has announced the opening of a new Charles River Accelerator and Development Lab facility on Chestnut Street in Somerville, Massachusetts, an emerging life sciences hub.